Author | Thรผrlimann, Beat. author |
---|---|
Title | Bisphosphonates in Clinical Oncology [electronic resource] : The Development of Pamidronate / by Beat Thรผrlimann |
Imprint | Berlin, Heidelberg : Springer Berlin Heidelberg, 1999 |
Connect to | http://dx.doi.org/10.1007/978-3-642-59845-6 |
Descript | XIV, 113p. 24 illus. online resource |
Physiology and Pathophysiology of Bone -- Natural History of the Skeleton -- Cortical Bone -- Trabecular Bone -- Composition of Bone -- Bone Cells -- Factors Regulating Calcium Homeostasis and Bone Resorption/Bone Formation -- References -- Bone Resorption -- Mechanisms of Local Bone Resorption -- References -- Bone Formation -- Cells of the Osteoblast Lineage -- Osteocalcin -- Other Bone Matrix Proteins -- Bone Mineralization -- References -- Factors Regulating Bone-resorbing Cells and Bone-forming Cells -- Parathyroid Hormone -- Calcitonin -- Vitamin D3 -- Prostaglandins -- Interleukin-1 -- Tumor Necrosis Factor and Lymphotoxin -- Interleukin-4 -- Interleukin-6 -- ?-Interferon -- Colony-stimulating Factors -- Osteoclast-forming Factor -- References -- Factors Regulating Bone Formation -- Transforming Growth Factor ? (TGF- ?) -- Fibroblast Growth Factors -- Platelet-derived Growth Factor -- Bone Morphogenetic Proteins -- Insulin-like Growth Factors -- References -- Pharmacological Treatment of Bone Disorders -- Estrogens and Antiestrogens -- Calcium -- Fluoride -- Vitamin D3/Calcitriol -- Phosphate Therapy -- References -- Bisphosphonates -- Pamidronate: From a Detergent in Washing Powder to a Registered Drug -- References -- Chemical Structure and Preclinical Evaluation -- Chemical Structure -- Biological Effects -- Pharmacokinetics -- Distribution -- References -- Hypercalcemia of Malignancy -- Magnitude of the Problem -- Pathogenesis -- Mediators -- Treatment -- Rehydration and Supportive Care -- Plicamycin (Mithramycin) -- Dialysis -- Bisphosphonates -- Other Bisphosphonates -- Gallium Nitrate -- Cisplatin -- References -- Malignant Osteolytic Bone Disease -- Magnitude of the Problem -- Interdisciplinary Management -- Etidronate -- Oral Formulations of Second- and Third-generation Bisphosphonates -- References -- Pamidronate -- Pharmacokinetics of Pamidronate in Patients with Bone Metastases -- References -- Pamidronate for Pain Control in Patients with Malignant Osteolytic Bone Disease: A Prospective Dose-Effect Study -- Patients and Methods -- Results -- Discussion -- Conclusion -- References -- A Prospective, Randomized, Dose-finding Study of Pamidronate in Patients with Malignant Osteolytic Bone Disease -- Patients and Methods -- Statistical Analysis -- Results -- Patients Characteristics -- Properties of LASA Scales and PSC -- Efficacy (LASA) -- Efficacy (PS, PSC, and Use of Analgesics) -- Efficacy (Laboratory Values) -- Treatment Duration -- Toxicity and Side Effects -- Multivariate Analysis -- Conclusion -- References -- Pamidronate Versus Controls in Patients with Metastatic Breast Cancer and Bone Metastases -- Pamidronate for Inhibition of Bone Progression in Patients with Advanced Breast Cancer: A Randomized, Multicenter Phase-III Trial -- Patients and Methods -- Results -- Discussion -- References -- Aredia in the Indication of Osteolytic Bone Metastases of Breast Cancer: A Model for Evaluation of Cost-Benefit -- References -- Prospective, Randomized, Double-blind, Dose-finding Study in Patients with Malignant Osteolytic Bone Metastases and Pain: 60 mg vs. 90 mg Pamidronate -- Aim of the Study -- Study Design -- Treatment -- Statistical Considerations -- Patient Characteristics -- Results -- Pain Intensity -- Responders/Nonresponders -- Pain Improvement -- Pain Frequency -- General Well-being -- Pain Score -- Performance Status -- Analgesic Score -- Total Bone Mineral Density -- Correlation of Results from Selected End Points -- Pain Intensity and Bone Mineral Density -- Correlation of Bone Mineral Density and Diagnosis -- Discussion -- References -- Cost-Effectiveness Analysis of Pamidronate Treatment in Patients with Advanced Malignant Osteolytic Bone Disease: SG 110/93 Plus -- Patients and Methods -- Results -- Conclusion -- Recent Developments and Future Directions -- Ibandronate -- Pamidronate -- Adjuvant Bisphosphonate Therapy -- Future Directions -- References